File

Stealth BioTherapeutics Submits Elamipretide New Drug Application to FDA for Treatment of Barth Syndrome

Retrieved on: 
Tuesday, August 24, 2021
Exercise intolerance, Company, Life expectancy, EMA, U.S. Securities and Exchange Commission, Human, Degenerative disease, Leber's hereditary optic neuropathy, SEC, Infection, Friedreich's ataxia, Security (finance), Duchenne muscular dystrophy, DNA, Hope, Nasdaq, Private Securities Litigation Reform Act, Food, Disease, Risk, IgG4-related ophthalmic disease, Marketing, NDA, Heart, Forward-looking statement, Lists of diseases, Review, Clinical trial, File, Elamipretide, Stealth, Safety, Patient, Eye, Barth syndrome, FDA, Heart failure, Brain, Annual report, COVID-19, Muscle weakness, Patent, Protalix BioTherapeutics, Drug development, Pharmaceutical industry

"We initiated our Barth syndrome development efforts at the request of the Barth syndrome community.

Key Points: 
  • "We initiated our Barth syndrome development efforts at the request of the Barth syndrome community.
  • Stealth believes, however, that the data could support an NDA review, and has accordingly submitted the NDA as requested by the Barth syndrome patient community.
  • Elamipretide was previously granted rare pediatric designation, fast track designation, and orphan drug designation by the FDA, and orphan drug designation by the EMA, for the treatment of Barth Syndrome.
  • Barth syndrome occurs almost exclusively in males and is estimated to affect one in 200,000 to 400,000 individuals worldwide.

AdTheorent Holding Company, LLC Announces Second Quarter 2021 Results

Retrieved on: 
Tuesday, August 24, 2021
MCAP, Proxy, Digital, Adjustment, Intention, SEC, Partner, Advertising, CFO, Risk, Solution, Frost & Sullivan, MRCC, Software, U.S. Securities and Exchange Commission, Communication, Investment, Projection, File, Prospectus, CEO, Suite, Sale, Form, GAAP, Person, Name, AI, NASDAQ, Goal, Failure, SPAC, EBITDA, View, Security (finance), Monroe, Company, Terminology, Private Securities Litigation Reform Act, LLC, TAC, Sumathi Best Television Current Reporting Award, Growth, Ownership, Acquisition, Multimedia, Illinois, Frost, Depreciation, COVID-19, Mobile phone, Video game, Financial services, Bank, Risk management

NEW YORK and CHICAGO, Aug. 24, 2021 /PRNewswire/ -- AdTheorent Holding Company, LLC ("AdTheorent" or "the Company"), a programmatic digital advertising leader using advanced machine learning technology and solutions to deliver real-world value for advertisers and marketers, today announced financial highlights for the second quarter ended June 30, 2021.

Key Points: 
  • NEW YORK and CHICAGO, Aug. 24, 2021 /PRNewswire/ -- AdTheorent Holding Company, LLC ("AdTheorent" or "the Company"), a programmatic digital advertising leader using advanced machine learning technology and solutions to deliver real-world value for advertisers and marketers, today announced financial highlights for the second quarter ended June 30, 2021.
  • Jim Lawson, Chief Executive Officer of AdTheorent stated, "Our accelerated growth in the second quarter of 2021 demonstrates the power of AdTheorent Predictive Advertising and the measurable value we provide to advertisers seeking top campaign performance using privacy-forward targeting methods.
  • On August 23, 2021, MCAP Acquisition Corporation (NASDAQ: MACQ) ("MCAP"), a publicly-traded special purpose acquisition company, sponsored by an affiliate of Chicago-based asset manager Monroe Capital LLC, filed its preliminary proxy statement / prospectus with the Securities and Exchange Commission (the "SEC") in connection with its proposed business combination with AdTheorent, which includes AdTheorent's complete second quarter 2021 financial results.
  • Actual results and the timing of events may differ materially from the results anticipated in these forward-looking statements.

PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

Retrieved on: 
Monday, August 23, 2021
Biotechnology, Diabetes, Health, Pharmaceutical, Oncology, Company, Liver, Capsule, Diabetes, LLC, Private Securities Litigation Reform Act, Form S-3, Program, Securities Act of 1933, Cancer, Form, PMCB, U.S. Securities and Exchange Commission, SEC, B cell, Food, Drug Master File, Ifosfamide, Cell, Act, Biotechnology, File, Clinical trial, NASDAQ, Form 10-K, IND, Prospectus, Investigational New Drug, Ascites, Sale, 3rd Floor, FDA, Pancreatic cancer, Neoplasm, Insulin, Regulation D, Park Avenue, Technology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Security (finance), Pharmaceutical industry

In a concurrent private placement, PharmaCyte also issued to the investors in the offering unregistered warrants to purchase up to an aggregate 7,000,000 shares of common stock.

Key Points: 
  • In a concurrent private placement, PharmaCyte also issued to the investors in the offering unregistered warrants to purchase up to an aggregate 7,000,000 shares of common stock.
  • Immediately following the closing of the registered direct offering and the concurrent private placement, the number of outstanding shares of common stock of the Company will be 18,979,465 and the Company will have approximately $90 million in cash in its bank account.
  • The warrants have an exercise price equal to $5.00 per share, are exercisable immediately upon issuance and will expire five years from the issuance date.
  • PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box.

AdTheorent Awarded Coveted Spot on Crain's New York Business 2021 Best Places to Work in New York City

Retrieved on: 
Monday, August 23, 2021
MCAP, Nasdaq, Growth, U.S. Securities and Exchange Commission, Technology, Form, Ownership, Direct access, Digital, Acquisition, SEC, Crain Communications, Policy, Security (finance), KPI, PTO, ROI, Name, Machine learning, AI, File, Multimedia, Illinois, NASDAQ, Goal, Frost, News, Partnership, Solution, CEO, Suite, Culture, Frost & Sullivan, View, Public relations, Cryptocurrency

AdTheorent's programmatic platform uses award-winning data science and machine learning (ML) capabilities to deliver advertiser-specific business outcomes for top consumer brands.

Key Points: 
  • AdTheorent's programmatic platform uses award-winning data science and machine learning (ML) capabilities to deliver advertiser-specific business outcomes for top consumer brands.
  • AdTheorent's proprietary suite of tools, methodologies and vertical solutions maximizes campaign performance and ROI for advertisers, while operating in a privacy-first manner.
  • AdTheorent was awarded "Best AI-Based Advertising Solution" (AI Breakthrough Awards) and "Most Innovative Product" (B.I.G.
  • For more information visit: https://www.mcapacquisitioncorp.com/
    Crain's New York Business provides news, information, analysis and connections on all facets of New York through the prism of business.

Standard Lithium Files Preliminary Base Shelf Prospectus

Retrieved on: 
Friday, August 20, 2021
Lithium, Company, NYSE American, Shelf, U.S. Securities and Exchange Commission, Vehicle registration plates of the Netherlands, Form, GLOBE, Area studies, Government, Private Securities Litigation Reform Act, TSX Venture Exchange, Mojave Desert, NYSE, File, Board, News, FRA, Sale, Sustainability Accounting Standards Board, SLI, Security (finance)

VANCOUVER, British Columbia, Aug. 20, 2021 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), an innovative technology and lithium project development company, announces that it has filed a preliminary short form base shelf prospectus (the “Shelf Prospectus”) with securities regulators in each of the provinces of Canada, except Quebec.

Key Points: 
  • VANCOUVER, British Columbia, Aug. 20, 2021 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (Standard Lithium or the Company) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), an innovative technology and lithium project development company, announces that it has filed a preliminary short form base shelf prospectus (the Shelf Prospectus) with securities regulators in each of the provinces ofCanada, except Quebec.
  • The Shelf Prospectus has not yet become final for the purpose of the sale of securities.
  • The specific terms of any future offering of securities (if any) will be set forth in a supplement to the Shelf Prospectus.
  • The Company has filed the Shelf prospectus for future financial flexibility and has no immediate intentions to undertake an offering.

Ardmore Shipping Completes Annual Review of Securities Filings

Retrieved on: 
Friday, August 20, 2021
Company, ATM, File, ASC, Transport, Program, Register, U.S. Securities and Exchange Commission, Form, SEC, Registration statement, ETP, Investment, NYSE, Sale, Security (finance)

HAMILTON, Bermuda, Aug. 20, 2021 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE:ASC) ("Ardmore" or the "Company") today announced that the Company has completed its annual review of its securities filings.

Key Points: 
  • HAMILTON, Bermuda, Aug. 20, 2021 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE:ASC) ("Ardmore" or the "Company") today announced that the Company has completed its annual review of its securities filings.
  • Ardmore owns and operates a fleet of MR product and chemical tankers ranging from 25,000 to 50,000 deadweight tonnes.
  • Ardmore provides its services to customers through voyage charters, commercial pools, and time charters, and enjoys close working relationships with key commercial and technical management partners.
  • Ardmore has established Ardmore Ventures as Ardmore's holding company for existing and future potential investments related to the Energy Transition Plan and completed its first projects under the ETP in June 2021.

AM Best Downgrades Credit Ratings of Crusader Insurance Company and Unico American Corporation; Places Credit Ratings Under Review With Negative Implications

Retrieved on: 
Friday, August 20, 2021
Insurance, Professional Services, Industry, Good, Pressure, AM Best, Insurance, Credit, CA, Erosion, ALL, Review, File, Marginal, News, AM, Data, Risk management

Concurrently, AM Best has downgraded the Long-Term ICR to b (Marginal) from bb (Fair) of Crusaders parent company, Unico American Corporation (Unico).

Key Points: 
  • Concurrently, AM Best has downgraded the Long-Term ICR to b (Marginal) from bb (Fair) of Crusaders parent company, Unico American Corporation (Unico).
  • These Credit Ratings (ratings) have been placed under review with negative implications.
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Bests Credit Ratings .
  • For information on the proper use of Bests Credit Ratings, Bests Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Bests Ratings & Assessments .

Xplore Announces Earn-In Option Agreement on Perrigo Lake Property, Red Lake Mining District, Ontario

Retrieved on: 
Friday, August 20, 2021
ACT, AS, AND, Agreement, TSX Venture Exchange, Vendor, File, Project, Gold, NSR, National instrument, Perrigo, Geology, Pringle, Good, South Tyrol Option Agreement, Disclosure, CEO, Vanadium, ANY, Legislation, Nanaimo, Mining, THIS, OR, Saindak Copper Gold Project, Copper, THE, Company, Ownership, Acquisition, Uchi, Karmutsen Formation, News, TSX, Valk, Ontario Geological Survey, Bookkeeping, Security (finance), Cryptocurrency

The transaction and the issuance of the shares contemplated by the Agreement are subject to the acceptance of the TSX.V.

Key Points: 
  • The transaction and the issuance of the shares contemplated by the Agreement are subject to the acceptance of the TSX.V.
  • Wes Hanson, P.Geo., President and CEO of Xplore, notes, "Perrigo Lake provides a third property in the Red Lake Mining Division, one of the premier locations in Canada for the discovery of gold mineralization.
  • Airborne magnetic surveys at Pringle and Upper Red Lake are scheduled to commence shortly and we expect that we will be able to include Perrigo Lake in the scope of work.
  • Our plan is to complete reconnaissance mapping and sampling of all three Red Lake properties in the fall."

Regencell Bioscience Holdings Limited Announces Partial Exercise of Underwriter’s Over-Allotment Option

Retrieved on: 
Friday, August 20, 2021
Science, Other Science, Biotechnology, Research, Alternative Medicine, General Health, Health, Mental Health, Company, TCM, Lists of diseases, File, Nasdaq, Loeb, Attention deficit hyperactivity disorder, U.S. Securities and Exchange Commission, Form, Traditional Chinese medicine, SEC, Research, ASD, Offering, Park Avenue, ADHD, Review, NASDAQ, Prospectus, Patient, Sale, Phrase, Exercise, Autism spectrum, SEC filing, Security (finance), Architecture

Gross proceeds from the Offering, including proceeds from the exercise of the over-allotment option, totaled US$24,937,500, before deducting underwriting discounts and other related expenses.

Key Points: 
  • Gross proceeds from the Offering, including proceeds from the exercise of the over-allotment option, totaled US$24,937,500, before deducting underwriting discounts and other related expenses.
  • The Company's ordinary shares began trading on the Nasdaq Capital Market on July 16, 2021 under the ticker symbol "RGC."
  • Regencell Bioscience Holdings Limited is an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (TCM) for the treatment of several neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD).
  • All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the Companys proposed Offering.

Seadrill Limited: First Half 2021 Results

Retrieved on: 
Friday, August 20, 2021
Industry, Rationalization, Company, File, Kolskaya (jack-up rig), Weather, Shipyard, Nature, United States bankruptcy court, SEC, Maintenance, Insurance, Bankruptcy, Organization, United Kingdom, Chapter 11, Title 11, United States Code, Carbon, OTC Markets Group, Contract, News, Attack, Annual report, COVID-19, Income, Global health, Security (finance), Risk management

"Seadrill has continued to operate effectively and safely throughout H1 2021, despite ongoing disruptions caused by COVID-19 challenging the industry's logistical capabilities.

Key Points: 
  • "Seadrill has continued to operate effectively and safely throughout H1 2021, despite ongoing disruptions caused by COVID-19 challenging the industry's logistical capabilities.
  • The filing of our Plan Support Agreement with strong creditor support marked the next step in this journey for Seadrill."
  • Seadrill is a leading offshore drilling contractor utilizing advanced technology to unlock oil and gas resources for clients across harsh and benign locations across the globe.
  • New factors emerge from time to time, and it is not possible for us to predict all of these factors.